THURSDAY, NOVEMBER 24 HALL A

SESSION 1

13:00-13:45	THE BEST OF RBMO 2021-2022	HALL A
Capsule	The three best papers published in RBMO in 2021 are presented in this session	ı .
Chairpersons	Bart Fauser, Netherlands	
	Zion Ben Rafael, Israel	
13:00-13:05	Welcome	
	Bart Fauser, Netherlands	
13:05-13:25	Effect of probiotics on the relative abundance of vaginal Ureaplasma parvum in	n women
	suffering from unexplained infertility	
	Michael Schenk, Austria	
13:25-13:45	Do fertility tracking apps offer women useful information about their fertile wi	ndow?
	Joyce Harper, UK	

SESSION 2

13:45-15:00	SCIENTIFIC MISCONDUCT, WHERE ARE WE TODAY	HALL A
Capsule	Whose job is it to identify fake publications?	
Chairpersons	Cornelis B. Lambalk, Netherlands	
13:45-14:00	Overall perspective	
	Lex Bouter, Netherlands	
14:00-14:20	The publisher perspective	
	Catriona Fennell, Netherlands	
14:20-14:40	The chief editor perspective	
	Bart Fauser, Netherlands	
14:40-15:00	Current status in reproductive medicine	
	Ben Mol, Australia	

SESSION 3

15:00-16:05	FEMALE HEALTHY AGING	HALL A
Capsule	With the ongoing trend towards increasing longevity, the determinant of healthy aging	
	generates increasing attention. Distinct gender differences are present, resu	•
	living longer in suboptimal health. How important are steroids, menopause,	
	reproductive dysfunction in this context? These issues will be addressed in g	reat detail by
	4 expert speakers.	
Chairpersons	Bart Fauser, Netherlands	
	Zion Ben Rafael, Israel	
15:00-15:05	Introduction	
	Bart Fauser, Netherlands	
15:05-15:20	Menopause and its implications	
	Dorenda van Dijken, Netherlands	
15:20-15:35	Wellbeing and sexual health	
	Alessandra Graziottin, Italy	
15:35-15:50	Gender differences in cardiovascular health	
	Angela Maas, Netherlands	
15:50-16:05	PCOS after menopause - morbidity and hormonal changes	
	Mats Brännström, Sweden	

16:05-16:20 BREAK

1

SESSION 4

16:20-17:40	PRECONCEPTIONAL (EPI)GENETICS, ETHICS AND LIFESTYLE CARE IN	HALL A
	PERSONALIZED MEDICINE	
Capsule	Personalized medicine requires an understanding of periconceptional needs.	
Chairpersons	Bart Fauser, Netherlands	
	Angela Maas, Netherlands	
16:20-16:40	Periconception (epi)genetics	
	Kevin Sinclair, UK	
16:40-17:00	Lifestyle, ethics and equity	
	Hafez Ismaili M'hamdi, Netherlands	
17:00-17:20	Periconception lifestyle care and personalized medicine	
	Régine Steegers-Theunissen, Netherlands	
17:20-17:40	Implications of COVID-19 on Fertility in Women and Men	
	Scott Nelson, United Kingdom	

SESSION 5

17:40-18:40 INDUSTRY SUPPORTED SESSION HALL A

SESSION 6

18:40- 19:40	OPENING SESSION: NOBEL PRIZE LAUREATE ROBERT G. EDWARDS ANNUAL HALL A
	LECTURE
Chairpersons	Zion Ben Rafael, Israel
	Bart Fauser, Netherlands
	Rene Frydman, France
	Joop Laven, Netherlands
18:40-19:30	Nobel prize laureate Robert G. Edwards annual lecture
	Uterine transplantation – the first treatment for absolute uterine factor infertility
	Mats Brännström, Sweden
19:30-19:40	Best Abstract Awards

1	NETV	VORK	RECEP	TION
---	------	------	-------	------

THURSDAY, NOVEMBER 24

LASER COURSE

14:00-16:45	INDUSTRY SUPPORTED COURSE	HALL C
-------------	---------------------------	--------

ART/INF/INFERTILITY FRIDAY, NOVEMBER 25

SESSION 1

08:30-10:00	PCOS	HALL A
Capsule	Many aspects of the most common endocrinopathy remain enigmatic.	
Chairpersons	Bart Fauser, Netherlands	
	Scott Nelson, UK	
08:30-08:55	Reproductive fitness in women with PCOS	
	Joop Laven, Netherlands	
08:55-09:15	Understanding PCOS: Diagnosis and treatment	
	Carlo Alviggi, Italy	
09:15-09:35	The endometrium in polycystic ovary syndrome	
	Johannes Ott, Austria	
09:35-10:00	Health in offspring of mothers with PCOS	
	Roger Hart, Australia	

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 2

10:20-11:50	PGT-A/PGS	HALL A
Capsule	PGT-a is a procedure limited by the biology of the preimplantation embryos?	
Chairpersons	Cornelis B. Lambalk, Netherlands	
	Ernesto Bosch, Spain	
10:20-10:45	PGT-A: Benefit or risk?	
	Sebastiaan Mastenbroek, Netherlands	
10:45-11:05	The ESHRE PGT consortium	
	Edith Coonen, Netherlands	
11:05-11:30	Why PGT-A cannot work and should be restricted to experimental protocols	
	Norbert Gleicher, USA	
11:30-11:50	ART has a selection problem: more treatments, more money spent, less babi	es
	Rita Vassena, Spain	

11:50-12:00 BREAK

SESSION 3

12:00-13:00	INDUSTRY SUPPORTED SESSION	HALL A
13:00-13:30	ORAL PRESENTATIONS	HALL A
Chairpersons		
13:00-13:07	Oral Abstract presentation	
13:07-13:14	Oral Abstract presentation	
13:14-13:21	Oral Abstract presentation	
13:21-13:28	Oral Abstract presentation	

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS SESSION 4

EXIBITION AREA

14:30-16:30	EMBRYO TRANSFER (ET) HALL A
Capsule	ET and Luteal support are not as simple as they seem to be.
Chairpersons	Ben Cohlen, Netherlands
	Ben Mol, Australia
14:30-15:05	Debate: Is HRT the 1st choice to prepare the endometrium for FET?
14:30	Yes: Bülent Urman , Turkey
14:40	No: Scott Nelson, UK
14:50	Discussion
15:05-15:40	<u>Debate</u> : Evaluation of the endometrium - Should we measure progesterone on the day of
	a frozen embryo transfer
15:05	Yes: Gijs Tecklenburg , <i>Netherlands</i>
15:15	No: Annalisa Racca, Spain
15:25	Discussion
15:40-15:47	Oral Abstract presentation
15:47-15:54	Oral Abstract presentation
15:54-16:30	Debate: Single embryo transfer should be the choice in all cases
15:54	Yes: Prevention of multiple pregnancy is the goal - Cornelis B. Lambalk, Netherlands
16:04	No: The myths behind elective single embryo transfer – Norbert Gleicher, USA
16:14	Discussion

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 5

16:50-18:20	ADD-ONS HALL A	
Capsule	Over 70% of IVF patients in the UK and Australia are offered one or more types of Add-	
	Ons. Is it justified?	
Chairpersons	Zion Ben Rafael, Israel	
	Rene Frydman, France	
16:50-17:15	Is endometrial scratching effective?	
	Ben Mol, Australia	
17:15-17:35	Should we keep doing assisted hatching?	
	Ben Cohlen, Netherlands	
17:35-18:00	ERA test - what proof do we have?	
	Max Ezzati, USA	
18:00-18:20	Why add-ons to IVF, likely, are the principal cause for declining IVF live birth rates all over	
	the world	
	Norbert Gleicher, USA	

ART/INF/INFERTILITY SATURDAY, NOVEMBER 26

SESSION 6

08:30-10:00	OVARIAN STIMULATION HALL A
Capsule	What can be done to improve ovarian stimulation?
Chairpersons	Rene Frydman, France
	Zion Ben Rafael, Israel
08:30-09:00	<u>Debate</u> : Ovarian stimulation, mild or wild or in between
08:30	Mild and Safe? Frank Broekmans, Netherlands
08:40	Personalized: Ernesto Bosch, Spain
08:50	Discussion
09:00-09:15	What is the optimal number of oocytes we should aim for with ovarian stimulation?
	Bart Fauser, Netherlands
09:15-09:35	The type of gonadotrophin for stimulation: Does it matter?
	Ernesto Bosch, Spain
09:35-10:00	Stimulation strategies for DOR
	Carlo Alviggi, Italy

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 7

10:20-11:50	HITECH IVF	HALL A
Capsule	These procedures need more proof before using it routinely in the clinic.	
Chairpersons	Rene Frydman, France	
	Catherine Racowsky, France	
10:20-10:45	IVM at time of OTC (Ovarian tissue cryopreservation)	
10.20-10.45	Claus Yding Andersen, Denmark	
10:45-11:05	Nuclear transplantation for patients with recurrent IVF failure	
	Jacques Cohen, USA (virtual)	
11:05-11:30	Rejuvenating the ovary by stem cell therapy	
	Nuria Pellicer, Spain (virtual)	
11:30-11:37	Oral Abstract presentation	
11:37-11:44	Oral Abstract presentation	
11:44-11:51	Oral Abstract presentation	
11:51-11:58	Oral Abstract presentation	

11:50-12:00 BREAK

SESSION 8

12:00-13:30	FERTILITY PRESERVATION	HALL A
Capsule	Fertility preservation use is growing and so are the doubts surrounding these	procedures
Chairpersons	Claus Yding Andersen, Denmark	
	Norbert Gleicher, USA	
12:00-12:35	<u>Debate</u> : Should we move from fertility preservation to oocytes donation fo	r young
	women with cancer? When?	
12:00	Preservation of fertility: Catherine Racowsky, France	
12:10	Prefer egg donation: Edgardo Somigliana, Italy	
12:20	Discussion	
12:35-12:55	Fertility preservation in oncological patients	
	Jacques Donnez, Belgium	
12:55-13:30	<u>Debate</u> : Asherman syndrome surgery or stem cells?	
12:55	Surgery: You don't need stem cells; you need good surgeons - Miriam Hansto	ede,
	Netherlands	
13:05	Stem cells: treat endometrial atrophy through tissue engineering - Nuria Pell	icier, Spain
	(virtual)	
13:15	Discussion	

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS

EXIBITION AREA

SESSION 9

14:30-16:30	ENDOMETRIOSIS AND INFERTILITY	HALL A
Capsule	The challenge is to select the best treatment	
Chairpersons	Norbert Gleicher, USA	
	Jacques Donnez, Belgium	
14:30-14:50	Endometriosis: Does it impact oocyte quality	
	Catherine Racowsky, France	
14:50-15:10	Endometriosis - surgery vs conventional ART for infertility	
	Edgardo Somigliana, Italy	
15:10-15:45	<u>Debate:</u> Long term risk of cancer in endometrioma: Immediate surgery, del	ayed surgery
	or never surgery?	
15:10	Delayed surgery: Jacques Donnez, Belgium	
15:20	Immediate surgery: Hans Nijman , <i>Netherlands</i>	
15:30	Discussion	
15:45-16:05	Fertility preservation in endometriosis: When should it be offered	
	Edgardo Somigliana, Italy	
16:05-16:30	Oral GnRH Antagonist for treatment of endometriosis	
	Nicholas Leyland, Canada (virtual)	

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

GYNECOLOGY FRIDAY, NOVEMBER 25

SESSION 1

08:30-10:00	DILEMMAS IN BENIGN GYNAECOLOGY	HALL B
Capsule	Dilemmas in daily care, which you must deal with. Concerning adnexal masses and heavy	
	menstrual bleeding.	
Chairpersons	Justin Clark, UK	
	Peggy Geomini, Netherlands	
08:30-08:45	What is the best referral policy for patients with an adnexal mass?	
	Peggy Geomini, Netherlands	
08:45-09:15	Differentiating benign form malignant cyst >> how to recognize less common types of	
	benign adnexal masses (struma ovarii/ Brenner tumor/ Sertoli Leydig cell)	
	Jeroen Kaijser, Netherlands	
09:15-09:30	Treatment options in case of HMB with intramural fibroids?	
	Tessel Cooijmans, Netherlands	
09:30-09:45	Is TLH really superior to abdominal hysterectomy?	
	Justin Clark, UK	
09:45-10:00	Endometrial ablation under local anesthetics - is it feasible?	
	Sergio Haimovich, Israel	

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 2

10:20-11:50	POI AND MENOPAUSE	HALL B
Capsule	Is genetics a routine tool for predicting menopause, understanding POI and personalized	
	clinical practice?	
Chairpersons	Micheline Misrahi, France	
	Nick Panay, UK	
10:20-10:40	New POI registry for a new era of global collaboration	
	Nick Panay, UK	
10:40-11:05	Over-view of genes involved in POI and physiological menopause. National genomics	
	projects	
	Micheline Misrahi, France	
11:05-11:25	Shared mechanism and genetics between the age of physiological menopau	ise, early
	menopause and POI	
	Yvonne Louwers, Netherlands	
11:25-11:50	Is there an association between menstrual cycle length and ovarian reserve	biomarkers
	during the reproductive life?	
	Bart Fauser, Netherlands	

11:50-12:00 BREAK

7

SESSION 3

12:00-13:30	UTERINE MALFORMATION	HALL B
Capsule	No agreement exists on the preferred current treatment of uterine malformation.	
Chairpersons	Pierluigi Benedetti Panici, Italy	
	Peggy Geomini, Netherlands	
12:00-12:15	T-Shaped, Y-Shaped, Dysmorphic – a real reproductive problem or a new trer	nd
	Sergio Haimovich, Israel	
12:15-12-45	<u>Debate</u> : Dysmorphic uterus, is it a real infertility problem? Is the solution su	ırgical?
12:15	Pro: Sergio Haimovich , <i>Israel</i>	
12:25	It is a real infertility problem, but the solution is not surgical: Ben Mol, Austro	alia
12:35	Discussion	
12:45-13:15	<u>Debate</u> : Uterine septum in infertility: To treat or not to treat?	
12:45	Pro: Jacques Donnez , <i>Belgium</i>	
12:55	Con: Justin Clark, UK	
13:05	Discussion	
13:15-13:30	Endometrial ablation under local anesthetics - is it feasible?	
	Sergio Haimovich, Israel	

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS

EXIBITION AREA

SESSION 4

14:30-16:30	MENOPAUSE HALL B	
Capsule	The suggestion to treat menopause with ovarian tissue reimplantation is highly	
	controversial.	
Chairpersons	Justin Clark, UK	
	Dorenda van Dijken, Netherlands	
14:30-14:50	Endocrine disruptors in fertility	
	Christian Egarter, Austria	
14:50-15:20	<u>Debate:</u> Should ovarian tissue reimplantation be considered for all women to postpon	e
	menopause	
14:50	Yes: Jacques Donnez, Belgium	
15:00	No: Mark Brincat, Malta	
15:10	Discussion	
15:10-15:35	Postmenopausal hormone treatment and the risk for malignancies	
	Johannes Ott, Austria	
15:35-16:00	Can AMH predict menopause	
	Frank Broekmans, Netherlands	
16:00-16:30	Progesterone from ovulatory menstrual cycles is a major cause of breast cancer	
	Herjan Coelingh Bennink, Netherlands	

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 5

16:50-18:20	HRT HALL B	
Capsule	The use of androgens and the length of HRT treatment are unsolved.	
Chairpersons	Christian Egarter, Austria	
	Nick Panay, UK	
16:50-17:25	<u>Debate</u> : Should androgens be routinely added to menopause treatment	
16:50	Yes: Alessandra Graziottin, Italy	
17:00	No: Dorenda van Dijken , <i>Netherlands</i>	
17:10	Discussion	
17:25-18:00	<u>Debate</u> : Hormone therapy started in premature or early menopause, should be	
	continued for life to prevent chronic diseases	
17:25	For: Nick Panay, UK	
17:35	Against: Mark Brincat, Malta	
17:45	Discussion	
18:00-18:20	Postmenopausal hormone treatment and the bone	
	Johannes Ott, Austria	

GYNECOLOGY

SATURDAY, NOVEMBER 26

SESSION 6

08:30-10:00	MANAGEMENT OF VULVOVAGINAL SYMPTOMS	HALL B
Capsule	Genitourinary syndrome of menopause (GSM) formerly "atrophic vaginitis" includes	
	genital symptoms of dryness, burning, and irritation, sexual symptoms of lack of	
	lubrication, discomfort, pain, impaired function and urinary symptoms of urgency, dysuria	
	and recurrent urinary tract infections. What is the best treatment?	
Chairpersons	Johannes Ott, Austria	
	Mark Brincat, Malta	
08:30-08:50	Anatomical and physiological changes of the vulvovaginal tract during peri-m	enopause
	Alessandra Graziottin, Italy	
08:50-09:35	<u>Debate:</u> Laser treatment is the first-line choice for Genitourinary Syndrome	of
	Menopause (GSM)?	
08:50	Yes: Zdenko Vizintin , <i>Slovenia</i>	
09:05	No: Dorenda van Dijken , <i>Netherlands</i>	
09:20	Discussion	
09:35-10:00	Sexual pain disorders, vestibulodynia and recurrent cystitis: The evil trio	
	Alessandra Graziottin, Italy	

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

SESSION 7

10:20-11:50	HPV	HALL B
Capsule	Special situations related to HPV vaccination	
Chairpersons	Ward Hofhuis, Netherlands	
	Diede Loopik, Netherlands	
10:20-10:40	HPV vaccination after treatment of CIN	
	Ruud Bekkers, Netherlands	
10:40-11:10	<u>Debate</u> : Should girls and boys both be vaccinated for HPV?	
10:40	Yes: Ralf van de Laar , <i>Netherlands</i>	
10:50	No: Marian Mourits, Netherlands	
11:00	Discussion	
11:10-11:30	The long-term risk of HPV-related disease after CIN3 treatment	
	Diede Loopik, Netherlands	
11:30-11:50	Treatment of HSIL with Imiquimod	
	Meike van de Sande, Netherlands	

11:50-12:00 BREAK SESSION 8

12:00-13:30	FERTILITY SPARING OPTIONS IN GYNECOLOGIC ONCOLOGY HALL B		
Capsule	Cancer patients should be informed of options for fertility preservation and future		
	reproduction prior to cancer treatment" (ASRM). However, gynecologists should be more		
	aware of the current options and results.		
Chairpersons	Pierluigi Benedetti Panici, Italy		
	Heleen van Beekhuizen, Netherlands		
12:00-12:20	Fertility- sparing management in recurrent gynecological cancer		
	Pierluigi Benedetti Panici, Italy		
12:20-12:45	Fertility-sparing management in young endometrial cancer patients		
	Heleen van Beekhuizen, Netherlands		
12:45-13:05	Fertility-sparing surgery in early-stage cervical cancer		
	Petra Zusterzeel, Netherlands		
13:05-13:30	New paradigm of ovarian cancer: More than meets the eye		
	Marian Mourits, Netherlands		

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS EXIBITION AREA SESSION 9

14:30-16:30	SLS - SOCIETY OF LAPAROSCOPIC & ROBOTIC SURGEONS HALL B
Chairperson	Jessica Ybanez Morano, USA
14:30-14:55	Cryo endometrial ablation another alternative
	Jessica Ybanez Morano, USA
14:55-15:15	The future of Minimally invasive surgery for the fertility patient
	Mona Orady, USA (virtual)
15:15-15:40	Laparoscopic Gynecologic Surgery Under Regional Neuraxial Anaesthesia: the Beginning of
	a New Era?
	Stefano Landi, Italy
15:40-16:00	Parametrial Endometriosis
	Thiers Soares, Brazil (virtual)
16:00-16:07	Oral Abstract presentation
16:07-16:14	Oral Abstract presentation
16:14-16:21	Oral Abstract presentation
16:21-16:28	Oral Abstract presentation

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING AND VISIT THE EXHIBITION

EXIBITION AREA

10

FETOMATERNAL MEDICINE FRIDAY, NOVEMBER 25

SESSION 1

08:30-10:00	PROGESTERONE & PROTECTION OF PREGNANCY - A PREIS SCHOOL HALL C		
_	ACADEMY SESSION		
Capsule	Progesterone (and not progestins) has shown multifaceted roles in pregnancy and recent		
	RCTS and metanalysis have confirmed a role of micronised progesterone in appropriate		
	dosage and timing to prevent recurrent miscarriage and preterm birth and manage		
	threatened miscarriage.		
Chairperson	Zion Ben Rafael, Israel		
08:30-08:35	Introduction		
	Zion Ben Rafael, Israel		
08:35-08:50	Progesterone support of the luteal phase		
	Paul Piette, Belgium		
08:50-09:15	Sporadic and recurrent miscarriage: Preventive tools		
	Adam Duvall, UK		
09:15-09:35	Preterm birth: Prediction and prevention		
	Gerard Visser, Netherlands		
09:35-09:55	Q&A		
09:55-10:00	Conclusion		

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION

EXHIBITION AREA

SESSION 2

3L33ION 2		
10:20-11:50	HOT CONTROVERSIES	HALL C
Capsule	Innovations in obstetrics	
Chairpersons	Basky Thilaganathan, UK	
Chairpersons	Amir Aviram, Canada	
10:20-10:50	Debate: cfDNA testing	
10:20	For Universal cfDNA testing by genome wide approach: Mireille Bekker,	Netherlands
10:30	Against genome wide cfDNA testing: Tina Buchholz, Germany	
10:40	Discussion	
10:50-11:05	Stem cells in obstetrics and gynecology	
10.50-11.05	Wolfgang Holzgreve, Germany	
11:05-11:20	Fetal surgery: Learning curve	
11.05-11.20	Luc Joyeux, Belgium (virtual)	
11:20-11:35	TTTS +/- sFGR: Long-term effects	
11:20-11:35	Jeanine van Klink, Netherlands	
11:35-11:50	Treatment of Rh disease	
11:35-11:50	Joanne Verweij, Netherlands	

11:50-12:00 BREAK

SESSION 3

12:00-13:30	HYPERTENSIVE DISORDERS HALL C	
Capsule	Hypertensive disorders are associated with underlying placental and maternal changes,	
	and are associated with endothelial dysfunction and vasospasm, leading to placental	
	insufficiency and serious consequences for the mother and infant.	
Chairpersons	Arie Franx, Netherlands	
	Gerard Visser, Netherlands	
12:00-12:20	What is new and controversial in hypertension in pregnancy?	
	Asma Khalil, UK	
12:20-12:45	The SNAP-HT trial: Optimal postpartum BP control	
	Paul Leeson, UK	
12:45-13:05	Does birth cure preeclampsia?	
	Basky Thilaganathan, UK	
13:05-13:30	New treatments to prevent complications	
	Emmanuel Attali, Israel	

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS

EXHIBITION AREA

SESSION 4

14:30-15:30	AN ARTIFICIAL WOMB FOR EXTREMELY PRETERM INFANTS	HALL C
Capsule	Is it possible and is it ethical to maintain alive an extremely premature baby?	
Chairpersons	Guid Oei, Netherlands	
	Mats Brännström, Sweden	
14:30-14:50	An artificial womb for extremely preterm infants	
	Guid Oei, Netherlands	
14:50-15:10	Development of a liquid-based incubator for extremely premature infants	
	Mark Schöberer, Germany	
15:10-15:30	Ethical aspects of the development of a liquid based incubator	
	Joanne Verweij, Netherlands	
15:30-16:30	MATERNAL VACCINATION	
Capsule	Offering maternal vaccination when its available, when do we reject the idea?	
Chairpersons	Kitty Bloemenkamp, Netherlands	
	Mireille Bekker, Netherlands	
15:30-15:50	Efficacy and safety of available maternal vaccinations: Update on available lit	erature (syst
	review)	
	Odette de Bruin, Netherlands	
	Emily Phijffer, Netherlands	
15:50-16:00	Maternal vaccinations: EMA's perspective	
	Corinne de Vries, Netherlands	
16:00-16:10	Maternal vaccinations: Patients perspective (Infant protection through mater	rnal
\Box 1	immunization, why do women accept or don't accept maternal vaccinations	
ĵ	Flor M. Munoz, USA	
16:10-16:30	Panel Discussion	

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION

EXHIBITION AREA

SESSION 5

16:50-18:20	GDM AND PRE-GDM	HALL C
Chairpersons	Yariv Yogev, Israel	
	Gerard Visser, Netherlands	
16:50-17:15	How to define well glycemic control	
	Yariv Yogev, Israel	
17:15-17:35	GDM in twins - More harm than a disease?	
	Nir Melamed, Canada	
17:35-18:00	Pragmatic approach for GDM diagnosis	
	Eran Ashwal, Canada	
18:00-18:20	What is the best pharmacological therapy for GDM? (Metformin\glyburide	e\insulin?)
	Yariv Yogev, Israel	

FETOMATERNAL MEDICINE SATURDAY, NOVEMBER 26 SESSION 6

08:30-10:00	INTRAPARTUM CARE HALL C	
Capsule	Simple procedures in obstetrics are so common and so controversial, why?	
Chairpersons	Liran Hiersch, Israel	
	Eran Ashwal, Canada	
08:30-08:50	Oxytocin use during labor	
	Inês Nunes, Portugal (virtual)	
08:50-09:15	When to perform an episiotomy	
	Katariina Laine, Norway	
09:15-09:35	Assisted vaginal delivery	
	Amir Aviram, Canada	
09:35-10:00	Diagnosing arrested labor	
	Diogo Ayres-de-Campos, Portugal (virtual)	

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION EXHIBITION AREA

SESSION 7

10:20-11:50	ROUND TABLE DISCUSSION	HALL C
Capsule	Hot controversies as seen by the experts	
Chairpersons	Gerard Visser, Netherlands	
	Yariv Yogev, Israel	
Discussants	Arie Franx, Netherlands	
	Basky Thilaganathan, UK	
	Asma Khalil, UK	
	Liran Hiersch, Israel	
	Nir Melamed, Canada	
	 Twins with asymptomatic mid-trimester short cervix. Cerclage? Proge Pessary? Neither? 	esterone?
	 CS or vaginal delivery in preterm delivery prior to 32, 28 weeks of ges 	tation
	Should all women be induced at 39 weeks, when of gestation?	
	• Can medical interventions mitigate adverse pregnancy outcomes rela (unconscious/conscious) biases of the health care workforce?	ted to
	Need for steroids at 34-37 weeks?	

11:50-12:00 BREAK

13

SESSION 8

12:00-13:30	OBESITY	HALL C
Capsule	Obesity and morbidity are related but can anything be done?	
Chairpersons	Yariv Yogev, Israel	
	Gerard Visser, Netherlands	
12:00-12:20	Diabetes or obesity- What affects more on the fetus and the mother?	
	Gerard Visser, Netherlands	
12:20-12:45	The impact of bariatric surgery on pregnancy outcome	
	Sam Schoenmakers, Netherlands	
12:45-13:05	Should obese women be advocated to lose weight in pregnancy?	
	Yariv Yogev, Israel	
13:05-13:30	Should all morbid obese women be induced at 38 weeks?	
	Arie Franx, Netherlands	

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS

EXHIBITION AREA

SESSION 9

14:30-15:10	CONTROVERSIAL ISSUES HALL C	
Capsule	Reducing twins is questionable and ethically controversial, should we do it and when?	
Chairpersons	Gerard Visser, Netherlands	
	Eran Ashwal, Canada	
14:30-15:00	Debate: Should we reduce twins to singleton?	
14:30	Yes: Yariv Yogev, Israel	
14:40	No: Yinon Gilboa , <i>Israel</i>	
14:50	Discussion	
15:00-16:30	PRETERM DELIVERY	
Capsule	How to assess and prevent premature delivery?	
15:00-15:20	US during labor	
	Yinon Gilboa, Israel	
15:20-15:35	Cervical length screening - does it vary in different populations?	
	Martijn Oudijk, Netherlands	
15:35-15:50	Pessary for preterm labor prevention – current evidence	
	Emmanuel Attali, Israel	
15:50-16:10	Cerclage – current evidence	
	Amir Aviram, Canada	
16:10-16:30	Special lecture: Non-invasive prenatal screening, both cell-based NIPS and with	
	proteomic based screening	
	Michael Sinosich, Australia	

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION

EXHIBITION AREA

SESSION 10

16:50-18:20	LABOR AND DELIVERY	HALL C
Chairpersons	Nir Melamed, Canada	
	Basky Thilaganathan, UK	
16:50-17:15	What week to operate HR gestation, (placenta previa, placenta accrete?	s/p more than 2
	CS)?	
	Hans Duvekot, Netherlands	
17:15-17:40	Can we screen routinely for placenta accrete and vasa previa?	
	Basky Thilaganathan, UK	
17:40-18:20	Debate: All twins should be delivered by CS	
17:40	Yes: Liran Hiersch, Israel	
17:50	No: Eran Ashwal, Canada	
18:00	Discussion	

ART/IVF/INFERTILITY FRIDAY, NOVEMBER 25

SESSION 1

08:30-10:00	MALE INFERTILITY LAB WORK HA	ALL D
Capsule	Have we made any progress in male infertility?	
Chairpersons	Scott Nelson, UK	
	Ans van Pelt, Netherlands	
08:30-08:55	Unraveling the causes of male infertility: The role of genetics	
	Frank Tüttelmann, Germany	
08:55-09:20	Genetic screening in male infertility: Time for new guidelines?	
	Manon Oud, Netherlands	
09:20-09:40	Scientific developments in male fertility preservation	
	Ans van Pelt, Netherlands	
09:40-10:00	Real-time sperm analysis using artificial intelligence at the time of ICSI: Correlation	on of
	single sperm characteristics with fertilization and blastocyst formation using SiD;	; a proof-
	of-concept	
	Alejandro Chavez-Badiola, UK	

10:00-10:20 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION EXHIBITION AREA

SESSION 2

10:20-11:50	DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS	HALL D
Chairpersons	Ben Cohlen, Netherlands	
	Ludovico Muzii, Italy	
Capsule	Endometriosis is a common inflammatory, estrogen-dependent condition associated with various symptoms affecting fertility and quality of life. Treatment ranges from "imperfect" medical options to surgical. Is the newly marketed oral GnRH receptors antagonist a gamechanger?	
10:20-10:50	Biomarkers in endometriosis Arne Vanhie, Belgium	
10:50-11:10	The role of US and MRI in diagnosis of DE Annemiek Nap, Netherlands	
11:10-11:35	Endometriosis: Is it a systemic disease? Ludwig Kiesel , <i>Germany</i>	
11:35-11:50	Treatment of endometriosis - surgical or medical? Jacques Maas, Netherlands	

11:50-12:00 BREAK

SESSION 3

12:00-13:30	FEMTECH AND FERTILITY: ARE WOMEN TAKING BACK CONTROL? HALL D
Chairpersons	Nick Macklon, UK Jacky Boivin, UK
Capsule	Review the booming field of wearable tech. Does it work? Where is it heading?
12:00-12:30	The rise and rise of Femtech in fertility Ying Cheong, UK
Capsule	Can apps provide effective psych support and help change behaviours?
12:30-13:00	Are apps replacing us? Who Cares? Jacky Boivin, UK
Capsule	Review and debate the motivations for egg freezing and the societal implications
13:00-13:30	Egg freezing- who is taking back control? Nick Macklon, UK

13:30-14:30 LUNCH BREAK, VISIT THE EXHIBITION AND MODERATED E-POSTERS

EXHIBITION AREA

SESSION 4

14:30-16:30	LABORATORY TECHNIQUES	HALL D
Capsule	Will AI ever replace the biologists?	
Chairpersons	Rita Vassena, Spain	
	Mina Popovic, Spain	
14:30-14:55	Has time-lapse technology finally proven its clinical benefit? Is it cost effective	e?
	Dorit Kieslinger, Netherlands	
14:55-15:20	Synthetic human entities with embryo-like features	
	Mina Popovic, Spain	
15:20-15:45	Blastulation rate: The golden KPI for self-evaluation in laboratory	
	Laura Rienzi, /taly	
15:45-16:10	AI will replace the embryologist in our lab: Yes, or no?	
	Alejandro Chavez-Badiola, UK	
16:10-16:30	Problems with using polygenic scores to select embryos	
	Patrick Turley, USA (virtual)	

16:30-16:50 COFFEE BREAK, E-POSTER VIEWING, AND VISIT THE EXHIBITION

EXHIBITION AREA

SESSION 5

16:50-18:20	FET (FROZEN EMBRYO TRANSFER) - TURKISH SOCIETY OF REPRODUCTIVE HALL D	
Chairpersons	MEDICINE SESSION Cem Atabekoglu, Turkey	
Chairpersons	Berrin Avci. Turkey	
16 50 17 05		
16:50-17:05	FET should be the first option for some patients	
	Işıl Kasapoğlu, Turkey	
17:05-17:20	Delayed versus immediate FET?	
	Esra Bulgan Kılıçdağ, Turkey	
17:20-17:35	Is there an ideal hormonal preparation for FET?	
	Gurkan Bozdag, Turkey	
17:35-17:50	Q&A	
17:50-18:20	PRO-CON discussion: PGT/A for Recurrent implantation failure & pregnancy loss	
	Moderator: Cem Atabekoglu, Turkey	
17:50	PRO: Sezcan Mumusoglu, Turkey	
18:00	CON: Bülent Urman , <i>Turkey</i>	
18:10	Discussion	